Immunochemical characterization of polysaccharide antigens from six clinical strains of Enterococci
© Hsu et al; licensee BioMed Central Ltd. 2006
Received: 24 March 2006
Accepted: 12 July 2006
Published: 12 July 2006
Enterococci have become major nosocomial pathogens due to their intrinsic and acquired resistance to a broad spectrum of antibiotics. Their increasing drug resistance prompts us to search for prominent antigens to develop vaccines against enterococci. Given the success of polysaccharide-based vaccines against various bacterial pathogens, we isolated and characterized the immunochemical properties of polysaccharide antigens from five strains of Enterococcus faecalis and one strain of vancomycin-resistant E. faecium.
We cultured large batches of each strain, isolated sufficient quantities of polysaccharides, analyzed their chemical structures, and compared their antigenic specificity. Three classes of polysaccharides were isolated from each strain, including a polyglucan, a teichoic acid, and a heteroglycan composed of rhamnose, glucose, galactose, mannosamine, and glucosamine. The polyglucans from all six strains are identical and appear to be dextran. Yields of the teichoic acids were generally low. The most abundant polysaccharides are the heteroglycans. The six heteroglycans are structurally different as evidenced by NMR spectroscopy. They also differ in their antigenic specificities as revealed by competitive ELISA. The heteroglycans are not immunogenic by themselves but conjugation to protein carriers significantly enhanced their ability to induce antibodies.
The six clinical strains of enterococci express abundant, strain-specific cell-surface heteroglycans. These polysaccharides may provide a molecular basis for serological typing of enterococcal strains and antigens for the development of vaccines against multi-drug resistant enterococci.
Enterococci are part of the normal flora of the gastrointestinal and genitourinary tracts and colonize the bowels of more than 90% of healthy humans . Enterococci are opportunistic pathogens with generally low virulence, but their intrinsic and increasing acquired resistance to multiple drugs have made them a major cause of nosocomial infections [2, 3]. Enterococci are intrinsically resistant to a number of antimicrobial drugs, including cell wall-active agents, many commercially available aminoglycosides, and vancomycin – the antibiotic of last resort against multidrug-resistant bacteria [4–7]. Enterococci can cause severe invasive infections such as peritonitis, endocarditis, meningitis, and abscesses in the urinary tract, along surgical sites, the lung and pleural spaces, facial sinuses, and peritoneal cavities [8, 9]. Because enterococci can spread rapidly among hospital patients and transfer their antibiotic resistance genes widely, even to other bacterial species, they may cause epidemics difficult to control and thus pose a significant threat to public health. The ever-increasing resistance of enterococci to multiple drugs prompts us to search for prominent antigens for the development of vaccines.
Enterococci are Gram-positive cocci that share morphology and Lancefield antigenicity with group D streptococci. Invasive Gram-positive pathogens, such as Streptococcus pneumoniae, are often encapsulated with weakly immunogenic polysaccharides (PSs). These PSs are major virulence factors. It has been found that the structural differences between capsular PSs form the molecular basis of serologic specificity for many species such as S. pneumoniae . Specific antibodies to S. pneumoniae PSs promote opsonization and phagocytosis and thereby confer protection against pneumococcal infection. Many successful antibacterial vaccines, such as ones against various serotypes of S. pneumoniae, type b of Haemophilus influenzae, and group C of Neisseria meningitides, have been developed based on their capsular PSs; and many other polysaccharide-based vaccines are under development . PSs and PS-synthesis genes have been noted to be widespread among enterococcal strains [12–15]. Enterococcal PSs have been demonstrated to play important roles in enterococcal pathogenesis, such as conferring resistance to phagocytosis . Furthermore, enterococcal PSs have been proposed as promising vaccine antigens [17–19].
Among enterococcal species, Enterococcus faecalis and E. faecium are the two major human pathogens, accounting for 85–89% and 10–15% of all enterococcal infections, respectively [8, 9]. Previous investigations have revealed that enterococci express surface PSs analogous to capsules of other pathogenic bacteria [20–23]. However, only a few types of enterococcal PSs have been characterized with respect to their structure and antigenicity, and then only partially so. It is not known whether strains of enterococci express different PSs, nor how many types of PSs exist within the enterococci family. On the hypothesis that cell-surface PSs of enterococci form an antigenic basis for serotyping and are promising vaccine candidates, we investigated and compared the immunochemical properties of PSs from six clinical strains of enterococci, including five strains of E. faecalis and one strain of vancomycin-resistant E. faecium.
Three different PSs were isolated from each enterococcal strain
To ease the PS isolation and purification, bacteria of each enterococcal strain were grown in dialyzed Columbia broth containing only nutrients with size less than 10 kDa, which were removed by dialysis later in the purification process. PSs, released by bacterial cells during fermentation, were found negligible when we attempted to isolate the PSs from the culture medium. Therefore, all PSs characterized in this study are cell-attached.
When blotted with sera raised against whole bacterial cells, column-eluting fractions corresponding to the dextran-like PS and the teichoic acids were reactive. Because the dextan-like PS fractions were contaminated with proteins, the immune reactivity is most likely due to the contaminants but not the PS. The reactivity of teichoic acids with immune sera is consistent with previous findings . The heteroglycans did not react with immune sera raised against the whole bacterial cells, indicating that these PSs are not natively immunogenic on the enterococcal cell surface.
Chemical structural analysis of heteroglycans
Monosaccharide composition of the heteroglycans was identified by GC-MS analysis of their corresponding alditol acetate derivatives. The analysis revealed that the heteroglycans isolated from the six strains of E. faecalis and E. faecium contained the same five monosaccharides, namely, rhamnose, glucose, galactose, mannosamine, and glucosamine. Furthermore, the mannosamine and glucosamine residues were N-acetylated as suggested by NMR analysis. Although these PSs contain the same components, five monosaccharides can form an enormous number of differently structured PSs by varying their sequences and linkage sites. Therefore, we relied on NMR spectroscopy to distinguish these PSs.
Immunological characterization of heteroglycans
To verify the antigenic specificity of the six heteroglycans, we obtained polyclonal antibodies against the heteroglycan PSs from E. faecium B210860 and E. faecalis type V. Because these PSs are not immunogenic in its native form, they were conjugated to tetanus toxoid. Both conjugates induced high titers of specific antibodies against the PSs. Therefore, the immunogenicity of these PSs can be significantly enhanced by conjugation to immunogenic protein carriers. If their specific antibodies are proven protective in future investigation, these PSs will become promising antigen candidates for enterococcal vaccines.
On the other hand, the binding between E. faecalis type V PS and its specific sera could be inhibited to various percentages by the PS from E. faecalis strain 68114, 324057B, and R19001 (Fig. 3B). E. faecalis type II PS showed minimal cross-reactivity with type V PS, supporting the contention that these two strains belong to different serotypes. PS from the vancomycin-resistant E. faecium B210860 did not show cross-reactivity with the type V PS, which was confirmed in both inhibition assays (Figs. 3A and 3B). PS from E. faecalis 68114 is highly cross-reactive with PS type V (Fig. 3B). Thus, both inhibition experiments and NMR analysis revealed that PSs from E. faecalis type V and 68114 are highly similar in structure and antigenicity. It is possible that these two PSs are the same antigen and that the subtle difference is the result of minor contamination in these PS preparations.
Various capsular or cell wall enterococcal PSs have been reported. In 1963, Wicken and Baddiley identified an intracellular glycerol teichoic acid containing various glucose substituents as the group antigen for group D streptococci, to which enterococci previously belonged . In 1973, Pazur et al. characterized an antigenic PS from E. faecalis consisting of a main chain of trisaccharide units joined with lactosyl and cellobiosyl side chains . In 1967, Bleiweis et al. reported a type 1 antigen containing glucose, rhamnose, glucosamine, galactosamine, ribitol, and phosphorus . In 1999, we characterized a teichoic acid consisting of glucose, glycerol, and phosphate common to several enterococcal strains [23, 24]. Recently, Hancock et al. suggested that rhamnopolysaccharides consisting of rhamnose, glucose, galactose, glucosamine, and galactosamine are an invariant component of E. faecalis cells [22, 28]. It is possible that the rhamnopolysaccharides and the heteroglycans in our study belong to the same category, e.g., they are both expressed at a similar cell surface location or serve similar functions in enterococcal physiology or pathogenesis.
We have isolated and characterized the chemical and immunological properties of various PSs from six clinical strains of E. faecium and E. faecalis. Each strain produces large amounts of a complex heteroglycan consisting of glucose, galactose, rhamnose, N-acetyl-mannosamine, and N-acetyl-galactosamine. These PSs are not natively immunogenic but can be converted to potent immunogens by conjugation to protein carriers. Analysis by NMR spectroscopy and antigenicity analysis by competitive ELISA inhibition revealed that heteroglycan PSs from E. faecium B210860 and E. faecalis types II and V are distinct antigens. PSs from E. faecalis strains 324057B and R19001 share some epitopes with type V, whereas E. faecalis 68114 PS is highly cross-reactive with type V PS. It is our hope that the heteroglycans may be used as the molecular basis for serotyping enterococcal strains and candidate antigens for the development of vaccines against multi-drug resistant enterococci.
A total of six clinical enterococcal strains were selected from a collection of clinical isolates. E. faecalis 68114 and vancomycin-resistant E. faecium B210860 were isolated from patients at the Brigham and Women's Hospital in Boston . E. faecalis 324057B was isolated from a patient at the Beth Israel Deaconess Medical Center in Boston . E. faecalis R19001 was an epidemic strain obtained from Boston Children's Hospital . E. faecalis type II and type V strains were isolated from patients in various hospitals in Japan . All isolates were grown in THB broth and 100-μl aliquots were stored in THB broth with 10% glycerol at -80°C.
To obtain sufficient amounts of PSs for chemical and immunological analysis, 16-L batch cultures were prepared for each strain in 20-L carboys with Columbia dialysate broth supplemented with 5% glucose and 0.005% hemin. The dialysate broth was prepared by dialyzing Columbia broth (Difco Laboratories, Detroit, MI) in deionized water with a membrane of 10 kDa cut-off to remove molecules larger than 10 kDa. The pH of the growth medium were maintained between 7 and 7.2 by titration with 10 M NaOH through an automatic pH controller (Cole-Parmer Instrument, Vernon Hills, IL), and the fermentation was terminated when the pH of the growth medium stabilized without addition of NaOH. Bacteria were typically grown at 37°C for 16–24 h. Culture samples were examined for contamination by Gram staining.
Isolation and purification of PSs
Bacterial cells were harvested by centrifugation at 4°C and washed in phosphate-buffered saline (PBS, 0.05 M phosphate, 0.15 M NaCl, pH 7). PSs were released from cell pellets by digestion with mutanolysin (50,000 units of enzyme per 100 g of wet cell) at 37°C for 16 h in 250 ml of buffer containing 40% sucrose, 30 mM phosphate (pH 7.0), 1 mM MgCl2, and 0.05% NaN3. After centrifugation, the supernatant was collected, dialyzed extensively against deionized water at 4°C, and lyophilized. The material was resuspended in a nuclease buffer (10 mM Tris, 10 mM CaCl2, and 10 mM MgCl2, pH 7.4) and treated with RNase A (0.5 mg/ml), DNase (0.1 mg/ml), and RNase T1 (5 μl/ml) at 37°C for 16 h, followed by digestion with proteinase K (0.1 mg/ml) at 56°C for 16 h. After centrifugation, the supernatant was collected, dialyzed extensively against deionized water; ethanol was added to a concentration of 30% and the mixture was chilled at 4°C for at least 6 hours to precipitate contaminating nucleic acids and proteins. After centrifugation, more ethanol was added to the supernatant to 80% concentration. PSs were precipitated at 4°C for 16 h and collected by centrifugation. Nuclease treatment and 30% ethanol precipitation were repeated until no significant amounts of proteins or nucleic acids were detected by UV absorption at 280 nm for protein contaminants and at 260 nm for nucleic acids and by ethidium bromide agarose gel for the absence of DNA.
The crude PS samples were further purified by size-exclusion and ion-exchange chromatography. The PS samples were first purified on Sephacryl S400 and S200 columns (Pharmacia Biotech, Piscataway, NJ). Eluted fractions were monitored by refractive index to detect PS and by UV absorption at 280 nm to detect protein contaminants. The carbohydrate content of each fraction was verified by phenol sulfuric acid assay. Fractions were also examined for immunogenicity by immunoblotting with rabbit antisera raised against the bacteria. Fractions positive with any of these four detection methods were pooled, dialyzed against deionized water, and lyophilized. They were further purified on an anion-exchange Q Sepharose column (Pharmacia Biotech, NJ), eluting with a linear gradient of NaCl from 0 to 1 M in 50 mM Tris buffer (pH 8.0). Similarly, fractions positive in the phenol-sulfuric acid assay or immunoblot were pooled, dialyzed, and lyophilized. To eliminate possible contaminants which may give false structural information, the heteroglycans were further purified by Superdex 200 column and analyzed by the same detection methods above.
Chemical structural analysis of PSs
All PS samples were analyzed by 1H nuclear magnetic resonance (NMR) spectroscopy. Sample preparation consisted of 1 mg dissolved in 0.7 ml of D2O. The spectra were acquired on a Varian Unity 500 spectrometer at 60°C. 1H chemical shifts were referenced to the HDO resonance at 4.45 ppm. The water signal was suppressed by pre-saturation during data acquisition.
Monosaccharide compositions of PSs were determined by GC-MS analysis of the alditol acetate derivatives as described . In brief, 0.05 mg of PS sample was completely hydrolyzed to monosaccharide components with 0.5 ml of 2 M trifluoroacetic acid at 110°C for 2 h, followed by reduction to their corresponding alditols with 5 mg of NaBH4 at room temperature for 2 h. Excess NaBH4 was removed by addition of 2 M HCl and drying under a stream of nitrogen, followed by addition of 0.5 ml of MeOH and drying under nitrogen. The alditols were converted to peracetates by treatment with 1 ml of 1:1 (vol.) mixture of acetic anhydride/pyridine at room temperature for 2 h. The alditol acetate derivatives were subjected to GC-MS analysis with a DB17 column on a Hewlett-Packard 6890/5973 GC-MS instrument. The GC run was started at 180°C, held for 2 min, and increased to 260°C by 2°C/min, and held at 260°C for 20 min. Standard alditol actetates corresponding to rhamnose, glucose, galactose, mannose, N-acetyl-glucosamine, N-acetyl-galactosamine, N-acetyl-mannosamine, and other typical monosaccharides were used for comparison in the GC-MS analysis.
Preparation of antisera specific for bacterial cells or PSs
Antisera to whole bacterial cells of E. faecalis types II and V and E. faecium B210860 were prepared. Bacteria were grown in 500 ml of Todd-Hewitt broth at 37°C until mid-log phase with OD650 of 0.4–0.5. Bacterial cells were harvested by centrifugation, washed with PBS, and fixed with 0.1% formalin at room temperature for 30 min. Three New Zealand white female rabbits, 1.5 kg, were used for immunization with the three strains of enterococcal cells. Rabbits were immunized intravenously with 0.1, 0.3, and 0.5 ml of 7 × 109 cfu/mL bacterial cells on day 1, 3, and 5, respectively. On the second, fourth, and fifth weeks, the rabbits was boosted with 0.5 ml of the bacterial cells three times a week. Immune sera were obtained one week after the last immunization and used for identification of naturally immunogenic PSs.
Antisera against the PSs from E. faecium B210860 and E. faecalis type V were prepared from rabbits immunized with conjugates of PS to tetanus toxoid. For the conjugate preparation, 2-mg samples of PSs were oxidized with 0.5 ml of 10 mM NaI4 at room temperature for 90 min, dialyzed, and lyophilized. The oxidized PS was reacted with 2 mg of tetanus toxoid in PBS with the addition of 10 mg of NaCNBH3. The conjugates were dialyzed and lyophilized. One New Zealand white rabbit, 1.5 kg, was immunized with each of the two conjugates. Rabbits were immunized three times by subcutaneous injection with 50 μg conjugate on weeks 1, 3, and 6. Complete Freund's adjuvant was used in the primary injection and incomplete Freund's adjuvant was used in the booster injections. Immune sera were collected one week after the last immunization and used for assessing the antigenic specificity of PSs.
Fluorescence confocal microscopy
E. faecalis type V and E. faecium B210860 were grown in glass-bottomed Petri dishes (MatTek, CA) with Todd-Hewitt broth to mid-log phase as determined by their growth curves. After being washed with PBS, bacterial cells were fixed with 1% paraformaldehyde at room temperature for 30 min. Cells were incubated with diluted (1:250) specific antisera at 37°C for 90 min, followed by incubation with Alexa Fluor 488-labeled goat-anti-rabbit IgG (Molecular Probes, CA) at 37°C for 90 min. Bacterial cells were washed and viewed by fluorescence confocal microscopy (Bio-Rad 1024MP system, Zeiss axiovert S100 cryton argon laser with 488 filter).
Competitive ELISA inhibition
Nunc-Immuno microtiter plates were coated with 100 μL of the selected PS-bovine serum albumin (BSA) conjugate (1 mg/mL for E. faecalis Type V and 0.25 mg/mL for E. faecium B210860) at 30°C for 4 h. PS-BSA conjugates were prepared similarly to those of PS-tetanus toxoid as described above. Plates were then washed with 10 mM Tris buffer five times. In the meantime, a series of mixing solutions were prepared on a separate plate by adding inhibitory PSs in 2-fold serial dilution. The concentrations of the PS inhibitors started at a concentration of 2.5 mg/mL (10× coating-antigen) for E. faecium B210860 PS-BSA coated plates and at 10 mg/mL for E. faecalis Type V PS-BSA coated plates. The mixing plates were then incubated at 30°C for 2 h and washed five times, followed by the addition of 75 μL antisera to each well. For the competitive inhibition, 100-μL solution containing inhibitor and antisera in the mixing plate was transferred from each well to the antigen-coated plate. The plate was incubated at 4°C overnight, followed by addition of 100 μL alkaline phosphatase conjugated goat anti-rabbit IgG to each well. The plate was incubated at 37°C for 2 h, washed five times, and 100 μL of substrate solution was added containing 1 mg/mL of p-nitrophenyl-phosphate in bicarbonate buffer (35 mM sodium carbonate, 0.01% w/w MgCl2, 0.02% w/w sodium azide, pH 10). Absorption at 405 nm was recorded and plotted against molar concentrations of the inhibitor. Percentage of inhibition was calculated from the difference with and without inhibitor vs. control.
We acknowledge financial support from the National Institute of Allergy and Infectious Disease of the National Institutes of Health (AI057926 and AI059500 to JYW and AI050667 to JH).
- Huycke MM, Sahm DF, Gilmore MS: Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis. 1998, 4 (2): 239-249.PubMed CentralView ArticlePubMedGoogle Scholar
- Tendolkar PM, Baghdayan AS, Shankar N: Pathogenic enterococci: new developments in the 21st century. Cell Mol Life Sci. 2003, 60 (12): 2622-2636. 10.1007/s00018-003-3138-0.View ArticlePubMedGoogle Scholar
- Moellering RCJ: Vancomycin-resistant enterococci. Clin Infect Dis. 1998, 26 (5): 1196-1199.View ArticlePubMedGoogle Scholar
- Klare I, Konstabel C, Badstubner D, Werner G, Witte W: Occurrence and spread of antibiotic resistances in Enterococcus faecium. Int J Food Microbiol. 2003, 88 (2-3): 269-290. 10.1016/S0168-1605(03)00190-9.View ArticlePubMedGoogle Scholar
- Smith DL, Johnson JA, Harris AD, Furuno JP, Perencevich EN, Morris JGJ: Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in Enterococcus faecium. Lancet Infect Dis. 2003, 3 (4): 241-249. 10.1016/S1473-3099(03)00581-4.View ArticlePubMedGoogle Scholar
- Murray BE: Vancomycin-resistant enterococcal infections. N Engl J Med. 2000, 342 (10): 710-721. 10.1056/NEJM200003093421007.View ArticlePubMedGoogle Scholar
- Woodford N: Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clin Microbiol Infect. 2005, 11 Suppl 3: 2-21. 10.1111/j.1469-0691.2005.01140.x.View ArticlePubMedGoogle Scholar
- Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, Sabetta J, Lyons RW: An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore). 1995, 74 (4): 191-200. 10.1097/00005792-199507000-00003.View ArticleGoogle Scholar
- Pintado V, Cabellos C, Moreno S, Meseguer MA, Ayats J, Viladrich PF: Enterococcal meningitis: a clinical study of 39 cases and review of the literature. Medicine (Baltimore). 2003, 82 (5): 346-364.View ArticleGoogle Scholar
- van Dam JE, Fleer A, Snippe H: Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek. 1990, 58 (1): 1-47. 10.1007/BF02388078.View ArticlePubMedGoogle Scholar
- Jones C: Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc. 2005, 77 (2): 293-324.View ArticlePubMedGoogle Scholar
- Hufnagel M, Hancock LE, Koch S, Theilacker C, Gilmore MS, Huebner J: Serological and Genetic Diversity of Capsular Polysaccharides in Enterococcus faecalis. J Clin Microbiol. 2004, 42 (6): 2548-2557. 10.1128/JCM.42.6.2548-2557.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Teng F, Jacques-Palaz KD, Weinstock GM, Murray BE: Evidence that the enterococcal polysaccharide antigen gene (epa) cluster is widespread in Enterococcus faecalis and influences resistance to phagocytic killing of E. faecalis. Infect Immun. 2002, 70 (4): 2010-2015. 10.1128/IAI.70.4.2010-2015.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu Y, Singh KV, Qin X, Murray BE, Weinstock GM: Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis. Infect Immun. 2000, 68 (2): 815-823. 10.1128/IAI.68.2.815-823.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu Y, Murray BE, Weinstock GM: A cluster of genes involved in polysaccharide biosynthesis from Enterococcus faecalis OG1RF. Infect Immun. 1998, 66 (9): 4313-4323.PubMed CentralPubMedGoogle Scholar
- Arduino RC, Murray BE, Rakita RM: Roles of antibodies and complement in phagocytic killing of enterococci. Infect Immun. 1994, 62 (3): 987-993.PubMed CentralPubMedGoogle Scholar
- Theilacker C, Krueger WA, Kropec A, Huebner J: Rationale for the development of immunotherapy regimens against enterococcal infections. Vaccine. 2004, 22 Suppl 1: S31-8.View ArticlePubMedGoogle Scholar
- Koch S, Hufnagel M, Theilacker C, Huebner J: Enterococcal infections: host response, therapeutic, and prophylactic possibilities. Vaccine. 2004, 22 (7): 822-830. 10.1016/j.vaccine.2003.11.027.View ArticlePubMedGoogle Scholar
- Huebner J, Quaas A, Krueger WA, Goldmann DA, Pier GB: Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci. Infect Immun. 2000, 68 (8): 4631-4636. 10.1128/IAI.68.8.4631-4636.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Bottone EJ, Patel L, Patel P, Robin T: Mucoid encapsulated Enterococcus faecalis: an emerging morphotype isolated from patients with urinary tract infections. Diagn Microbiol Infect Dis. 1998, 31 (3): 429-430. 10.1016/S0732-8893(98)00027-3.View ArticlePubMedGoogle Scholar
- Bottone EJ: Encapsulated Enterococcus faecalis: role of encapsulation in persistence in mouse peritoneum in absence of mouse lethality. Diagn Microbiol Infect Dis. 1999, 33 (1): 65-68. 10.1016/S0732-8893(98)00125-4.View ArticlePubMedGoogle Scholar
- Hancock LE, Gilmore MS: The capsular polysaccharide of Enterococcus faecalis and its relationship to other polysaccharides in the cell wall. Proc Natl Acad Sci U S A. 2002, 99 (3): 1574-1579. 10.1073/pnas.032448299.PubMed CentralView ArticlePubMedGoogle Scholar
- Huebner J, Wang Y, Krueger WA, Madoff LC, Martirosian G, Boisot S, Goldmann DA, Kasper DL, Tzianabos AO, Pier GB: Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun. 1999, 67 (3): 1213-1219.PubMed CentralPubMedGoogle Scholar
- Wang Y, Huebner J, Tzianabos AO, Martirosian G, Kasper DL, Pier GB: Structure of an antigenic teichoic acid shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Carbohydr Res. 1999, 316 (1-4): 155-160. 10.1016/S0008-6215(99)00046-4.View ArticlePubMedGoogle Scholar
- Wicken AJ, Baddiley J: Structure of intracellular teichoic acids from group D streptococci. Biochem J. 1963, 87: 54-62.PubMed CentralView ArticlePubMedGoogle Scholar
- Pazur JH, Cepure A, Kane JA, Hellerquist CG: Glycans from streptococcal cell walls. The molecular structure of an antigenic diheteroglycan of glucose and galactose from Streptococcus faecalis. J Biol Chem. 1973, 248 (1): 279-284.PubMedGoogle Scholar
- Bleiweis AS, Young FE, Krause RM: Cell walls of group D streptococci. II. Chemical studies on the type 1 antigen purified from the autolytic digest of cell walls. J Bacteriol. 1967, 94 (5): 1381-1387.PubMed CentralPubMedGoogle Scholar
- Hancock LE, Shepard BD, Gilmore MS: Molecular analysis of the Enterococcus faecalis serotype 2 polysaccharide determinant. J Bacteriol. 2003, 185 (15): 4393-4401. 10.1128/JB.185.15.4393-4401.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Rhinehart E, Smith NE, Wennersten C, Gorss E, Freeman J, Eliopoulos GM, Moellering RCJ, Goldmann DA: Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med. 1990, 323 (26): 1814-1818.View ArticlePubMedGoogle Scholar
- Maekawa S, Yoshioka M, Kumamoto Y: Proposal of a new scheme for the serological typing of Enterococcus faecalis strains. Microbiol Immunol. 1992, 36 (7): 671-681.View ArticlePubMedGoogle Scholar